Search results

Found 5,186 pages
AUTHOR: Kevin Grogan

Results per page

10 20 50 100

Sort by

Relevance Date

19 Sep 2013:

Skyepharma's Flutiform in COPD trials

The UK’s Skyepharma says that partner Mundipharma has commenced an international clinical trial of the firms’ asthma drug Flutiform for the treatment of chronic obstructive pulmonary disease.  - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/skyepharmas_flutiform_in_copd_trials_1005720

3 Aug 2012:

Pfizer sells Sandwich site

Pfizer has finally found a buyer for its Sandwich site in Kent, having completed the sale to a private consortium. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/pfizer_sells_sandwich_site_976851

9 May 2014:

Europe approval for GSK/Theravance COPD drug

GlaxoSmithKline and partner Theravance are celebrating after the European Commission granted marketing authorisation for their chronic obstructive pulmonary disease Anoro. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/europe_approval_for_gsktheravance_copd_drug_1001914

4 Feb 2015:

Genmab multiple myeloma drug shines in Phase II

Genmab and partner Johnson & Johnson have been boosted by positive mid-stage data on daratumumab for multiple myeloma. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/genmab_multiple_myeloma_drug_shines_in_phase_ii_970988

22 May 2013:

Europe approves Baxter/Halozyme's HyQvia

The European Commission has given the green light to Baxter International and Halozyme Therapeutics' HyQvia as replacement therapy for adults with primary and secondary immunodeficiencies. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/europe_approves_baxterhalozymes_hyqvia_1005059

9 Jul 2012:

Bayer progress on long-acting haemophilia drug

Bayer has started to enroll patients in an international Phase II/III trial to evaluate a new treatment for haemophilia A. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/bayer_progress_on_long-acting_haemophilia_drug_976999

18 Oct 2013:

FDA employees return to work

FDA employees return to work - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/fda_employees_return_to_work_1005871

12 Jul 2010:

Roche signs neurological pact with UK’s MRC

Roche’s Genentech unit has entered into an agreement with MRC Technology for an exclusive licence to a series of small molecule drug candidates for the potential treatment of neurological disease. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/roche_signs_neurological_pact_with_uks_mrc_982946

15 Jan 2015:

AZ gets boost from Brilinta data

AstraZeneca is celebrating after top-line results from a closely-watched trial of its potential blockbuster Brilinta demonstrated that the bloodthinner demonstrated statistically significant reductions in major cardiovascular thrombotic events in

by Kevin Grogan

https://www.pharmatimes.com/news/az_gets_boost_from_brilinta_data_970868

22 Nov 2011:

UCB acquires Lectus assets

UCB has acquired the key pharmaceutical assets of the UK's Lectus Therapeutics, boosting its efforts in the central nervous system field. - News - PharmaTimes

by Kevin Grogan

https://www.pharmatimes.com/news/ucb_acquires_lectus_assets_980012